Article Text

Download PDFPDF
Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Study design


randomised controlled trial (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes [RECORD]). NCT00379769.




blinded (outcome adjudication committee).*

Study question


364 centres in 25 countries in Europe and Australasia.


4458 patients 40–75 years of age (mean age 58 y, 52% men) who had type 2 diabetes, body mass index >25 (mean 31) kg/m2, and haemoglobin (Hb) A1c concentration >7.0% to 9.0% (mean 7.9%) on maximum doses of metformin (MFN) or sulphonylurea (SFU). Exclusion criteria included hospital admission for a major cardiovascular (CV) event in ⩽3 months, planned CV intervention, and heart failure (HF).


rosiglitazone (RGZ), 4 mg/day, plus MFN or SFU, with starting doses determined by local practice (n = 2220); or MFN plus SFU (control) (n = 2227). Drug doses …

View Full Text


  • Source of funding GlaxoSmithKline.